On the evening of August 4, CCTV-2's "Economic Half Hour" broadcast a report titled "The 'New Three New Products' Gather Energy for Improvement: Innovative Drugs Go Global and Open Up New Horizons", which provides a comprehensive account of the trend in Chinese innovative drugs. Haisco Medicine Group made a remarkable appearance as a representative of Chinese innovative drugs. It is also the second time in the past month that Haisco has appeared on CCTV.

↑ Click to play the video

According to the report, in Chengdu, innovative drugs exported overseas have adopted a "fast-paced" model.This is a pharmaceutical company in Wenjiang District, Chengdu, and several new drugs are being developed in the laboratory in an orderly manner.

The company, established in 2000, primarily focused on generic drugs in its early years. In the first half of this year, they quickly reached four innovative drug licensing agreements, with a potential total transaction value exceeding $6 billion.

After more than ten years of continuous research and development, the company has launched several innovative drugs in key therapeutic areas such as anesthesia and pain relief, chronic disease metabolism, respiration, and autoimmune diseases. In May this year, an independently developed anesthetic innovation drug was approved for market release in the United States. In the first quarter of 2026, the company achieved a net profit of 550 million yuan, a 1090% increase compared to the previous year.

Source: CCTV-2 "Economic Half Hour"